We hypothesized that by targeting the PKR/eIF2α pathway we would be able to normalize the synaptic function, thereby laying a theoretical foundation for the treatment of cognitive dysfunction in neurological patients with WD. This evidence concerns the gene EIF2AK2 and Wilson disease.